GlassScriptPhysician profile
Sindhu Garg
NPI 1770623894
$5,475.78
in general payments reported to CMS, 2019-2025
28 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $304 · 2021: $295 · 2022: $981 · 2023: $939 · 2024: $1,330 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $96.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.08 |
| Education | $96.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $617.24 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $569.31 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $557.79 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $526.42 | 2021-2025 | |
| Amgen INC. | $414.37 | 2019-2025 | Krystexxa, Tavneos |
| Aurinia Pharma U.S., INC. | $371.34 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $339.32 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $246.84 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $225.57 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Akebia Therapeutics INC | $189.09 | 2021-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $138.46 | 2022-2024 | Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $135.72 | 2019-2023 | Rayaldee |
| Novo Nordisk INC | $125.12 | 2020-2025 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $122.76 | 2020-2023 | Acthar |
| Horizon Therapeutics Plc | $114.65 | 2019-2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.62 | 2023-2025 | |
| Organogenesis INC. | $105.09 | 2023 | Apligraf |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.73 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $85.22 | 2025 | |
| Cardiovascular Systems INC. | $80.01 | 2022 | |
| Alexion Pharmaceuticals, INC. | $67.78 | 2020-2023 | Ultomiris |
| Glaxosmithkline, LLC. | $56.16 | 2021-2023 | Benlysta |
| Apellis Pharmaceuticals, INC. | $55.57 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $33.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2022 | |
| Genzyme Corporation | $21.19 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.63 | 2022 | |
| Baxter Healthcare | $14.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.